Author

J. Wu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.

The addition of camrelizumab to neoadjuvant docetaxel plus carboplatin significantly increased the pCR rate in patients with stage II-III TNBC, with a manageable safety profile.

D. Jiao, X. Sun, J. Qiao et al. · Annals of Oncology · 0 citations

Review Open access Aug 2026

Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial

Findings support the use of paclitaxel oral solution as a viable alternative second-line option for gastric cancer and show a lower incidence of neuropathy, hypersensitivity reactions, alopecia, and musculoskeletal and connective tissue disorders.

J. Li, M. Huang, T. Deng et al. · ESMO Open · 0 citations